Carnitine palmitoyltransferase 2 (CPT2) and mitochondrial beta-oxidation enzymes (CPT2)

Carnitine palmitoyltransferase 2 (CPT2) is an essential enzyme located on the inner mitochondrial membrane that plays a critical role in the carnitine shuttle system (UniProt P23786). It works in conjunction with carnitine palmitoyltransferase 1 (CPT1) to transport long-chain fatty acids into the mitochondrial matrix for energy production. Specifically, CPT2 converts long-chain acylcarnitines back into acyl-CoA esters, which then enter the mitochondrial beta-oxidation pathway (StatPearls, Fatty Acid Oxidation). This pathway consists of a series of enzymes—including acyl-CoA dehydrogenases and thiolases—that sequentially break down fatty acids to generate acetyl-CoA, NADH, and FADH2. Deficiencies in CPT2 or other beta-oxidation enzymes lead to severe metabolic disorders characterized by hypoketotic hypoglycemia, cardiomyopathy, and exercise-induced rhabdomyolysis (PubMed, PMID: 25559446). In a therapeutic context, these enzymes are targeted to modulate metabolic flexibility, such as in the treatment of angina or heart failure. Drugs like perhexiline and ranolazine inhibit these processes to shift metabolism from fatty acids to glucose, improving oxygen efficiency in the heart (PubChem, CID 4743). However, pharmacological inhibition must be carefully managed to avoid systemic metabolic crisis or organ toxicity such as hepatotoxicity (PubMed, PMID: 15606309).

Other names

CPT IICarnitine palmitoyltransferase type IIMitochondrial fatty acid beta-oxidation pathwayCPT2CPT-2

Inhibition of the carnitine shuttle (via CPT2) or specific enzymes in the mitochondrial beta-oxidation spiral to reduce fatty acid utilization and promote glucose oxidation for improved metabolic efficiency in ischemic tissues.